Ju Hee Kim et al., Arch Can Res 2017, 5:4 DOI: 10.21767/2254-6081-C1-003

## conferenceseries.com

### **International Conference on**

# CANCER EPIGENETICS AND BIOMARKERS

October 26-28, 2017 Osaka, Japan

### Calsequestrin-2 regulates migration and invasion in breast cancer cells

Ju Hee Kim, Bok Sil Hong, Wonsik Han, Dong-Young Noh and Hyeong-Gon Moon Seoul National University Hospital, South Korea

Calsequestrin (CASQ) is a Ca<sup>2+</sup>-binding protein localized in the endoplasmic/sarcoplasmic reticulum (ER/SR), an intracellular Ca<sup>2+</sup> release and storage of muscle. *CASQ2* forms a complex with Ryanodine Receptor-2 (RyR2) luminal calcium release channel and the intrinsic membrane proteins Triadin and junction in cardiac muscle. Ca<sup>2+</sup> is a sequester and regulator of diverse cellular processes and specific Ca<sup>2+</sup> channels play important roles in cell proliferation and invasiveness of breast cancers. To know the role of *CASQ2* in breast cancer cells, we established *CASQ2* over-expressing stable cells in Hs578T cells using retrovirus. *CASQ2* over-expressing Hs578T cells showed higher level of migration and invasion rate compared to Hs578T, which indicated that overexpression of *CASQ2* related with cellular functions. We also found that *CASQ2* over-expression elevates extracellular signal-related kinase (ERK) expression. In epidermal growth factor (EGF) treated cells, CASQ2 over-expressing Hs578T had higher phosphorylated ERK compared to Hs578T. The results from this study show a possible cause of migration and invasiveness in breast cancer cells. Taken together, these findings demonstrate that CASQ2 could be a new therapeutic target for breast cancer.

#### **Biography**

Ju Hee Kim is currently working as a Research Fellow in Seoul National University Hospital, Seoul, South Korea. She has completed her PhD in Life Science, Ewha Womans University and Post-Doctorate in Catholic-Harvard Wellman Photomedicine Center, Seoul, South Korea.

jhsubzero@naver.com

**Notes:**